2024

• Pétremand R, Chiffelle J, Bobisse S, Perez MAS, Schmidt J, Arnaud M, Barras D, Lozano-Rabella M, Genolet R, Sauvage C, Saugy D, Michel A, Huguenin-Bergenat AL, Capt C, Moore JS, De Vito C, Labidi-Galy SI, Kandalaft LE, Dangaj Laniti D, Bassani-Sternberg M, Oliveira G, Wu CJ, Coukos G, Zoete V, Harari A. Identification of clinically relevant T cell receptors for personalized T cell therapy using combinatorial algorithms. Nat Biotechnol. 2024 May 7. doi: 10.1038/s41587-024-02232-0. Epub ahead of print. PMID: 38714897.

• Courtès MG, Kountouri M, Wang W, Tille JC, Petignat P, Undurraga M, Labidi-Galy SI. Window of opportunity with PD1 blockade before chemoradiotherapy for an advanced stage clear cell carcinoma of the cervix. Gynecol Oncol Rep. 2024 Apr 14;53:101394.

• Balmaña J, Fasching PA, Couch FJ, Delaloge S, Labidi-Galy I, O’Shaughnessy J, Park YH, Eisen AF, You B, Bourgeois H, Gonçalves A, Kemp Z, Swampillai A, Jankowski T, Sohn JH, Poddubskaya E, Mukhametshina G, Aksoy S, Timcheva CV, Park-Simon TW, Antón-Torres A, John E, Baria K, Gibson I, Gelmon KA; LUCY investigators. Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY. Breast Cancer Res Treat. 2024 Apr;204(2):237-248.

2023

• Py C, De Vito C, Tsantoulis P, Kaya G, Labidi-Galy SI, Dietrich PY. Characteristics of long-survivor metastatic melanoma after polychemotherapy and interferon: a retrospective study. Swiss Med Wkly. 2023 Dec 15;153:3504. 

• Sandoval JL, Labidi-Galy SI. Shallow whole genome re-sequencing to precisely predict benefit from PARP inhibitor. Oncogene. 2023 Nov;42(48):3543-3544.

• Zielli T, Labidi-Galy I, Del Grande M, Sessa C, Colombo I. The clinical challenges of homologous recombination proficiency in ovarian cancer: from intrinsic resistance to new treatment opportunities. Cancer Drug Resist. 2023 Jul 28;6(3):499-516. 

• Romanens L, Chaskar P, Marcone R, Ryser S, Tille JC, Genolet R, et al. Clonal expansion of intra-epithelial T cells in breast cancer revealed by spatial transcriptomics. Int J Cancer. 2023 Jun 12

• Lang N, Ayme A, Ming C, Combes JD, Chappuis VN, Friedlaender A, et al. Chemotherapy-related agranulocytosis as a predictive factor for germline BRCA1 pathogenic variants in breast cancer patients: a retrospective cohort study. Swiss Med Wkly. 2023 Mar 30;153:40055.

   
• Maillard J, Elia N, Ris F, Courvoisier DS, Zekry D, Labidi Galy I, et al. Changes of health-related quality of life 6 months after high-risk oncological upper gastrointestinal and hepatobiliary surgery: a single-centre prospective observational study (ChangeQol Study). BMJ Open. 2023 Feb 22;13(2):e065902.

• Labidi-Galy SI, Rodrigues M, Sandoval JL, Kurtz JE, Heitz F, Mosconi AM, et al. Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysis. Ann Oncol. 2023 Feb;34(2):152–62.
• Lang N, Diciola A, Labidi-Galy I, Ris F, Di Marco M, Mach N, et al. Nab-PIPAC: a phase IB study protocol of intraperitoneal cisplatin and nab-paclitaxel administered by pressurised intraperitoneal aerosol chemotherapy (PIPAC) in the treatment of advanced malignancies confined to the peritoneal cavity. BMJ Open. 2023 Jan 5;13(1):e067691.

2021

• Bordry, N., Addeo, A., Jaksic, C., Dutoit, V., Roux-Lombard, P., Shah, D. P., Shah, P. K., Gayet-Ageron, A., Friedlaender, A., Bugeia, S., Gutknecht, G., Battagin, A., Di Marco, M., Simand, P. F., Labidi-Galy, I., Fertani, S., Sandoval, J., Dietrich, P. Y., & Mach, N. (2021). Humoral and cellular immunogenicity two months after SARS-CoV-2 messenger RNA vaccines in patients with cancer. iScience, 25(1), 103699.
• Vanacker, H., Harter, P., Labidi-Galy, S. I., Banerjee, S., Oaknin, A., Lorusso, D., & Ray-Coquard, I. (2021). PARP-inhibitors in epithelial ovarian cancer: Actual positioning and future expectations. Cancer treatment reviews, 99, 102255.
• Addeo, A., Shah, P. K., Bordry, N., Hudson, R. D., Albracht, B., Di Marco, M., Kaklamani, V., Dietrich, P. Y., Taylor, B. S., Simand, P. F., Patel, D., Wang, J., Labidi-Galy, I., Fertani, S., Leach, R. J., Sandoval, J., Mesa, R., Lathrop, K., Mach, N., & Shah, D. P. (2021). Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer. Cancer cell, 39(8), 1091–1098.e2.
• Gelmon, K. A., Fasching, P. A., Couch, F. J., Balmaña, J., Delaloge, S., Labidi-Galy, I., Bennett, J., McCutcheon, S., Walker, G., O’Shaughnessy, J., & Collaborating Investigators (2021). Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis. European journal of cancer (Oxford, England : 1990), 152, 68–77.
• Olivier T, Fernandez E, Labidi-Galy I, Dietrich PY, Rodriguez-Bravo V, Baciarello G, Fizazi K, Patrikidou A. Redefining cancer of unknown primary: Is precision medicine really shifting the paradigm? Cancer Treat Rev. 2021 Apr 5;97:102204.
• Meier RPH, Muller YD, Dietrich PY, Tille JC, Nikolaev S, Sartori A, et al. Immunologic Clearance of a BK Virus-associated Metastatic Renal Allograft Carcinoma. Transplantation. 2021 Feb 1;105(2):423–9.

2020

• Samartzis EP, Labidi-Galy SI, Moschetta M, Uccello M, Kalaitzopoulos DR, Perez-Fidalgo JA, Boussios S. Endometriosis-associated ovarian carcinomas: insights into pathogenesis, diagnostics, and therapeutic targets-a narrative review. Ann Transl Med. 2020 Dec;8(24):1712.
• Le Saux O, Ray-Coquard I, Labidi-Galy SI. Challenges for immunotherapy for the treatment of platinum resistant ovarian cancer. Semin Cancer Biol. 2020 Sep 12:S1044-579X(20)30193-0.
• Terzic J, Seipel A, Dubuisson J, Tille JC, Tsantoulis P, Addeo A, Labidi-Galy SI. Sustained response to pembrolizumab without prior chemotherapy in high-grade serous ovarian carcinoma with CSMD3 mutation. Gynecol Oncol Rep. 2020 Jun 15;33:100600.
• Labidi-Galy SI. Pathogenesis of ovarian cancer. 2020;DOI : 10.13097/archive-ouverte/unige:136866
• De Talhouet S, Peron J, Vuilleumier A, Friedlaender A, Viassolo V, Ayme A, Bodmer A, Treilleux I, Lang N, Tille JC, Chappuis PO, Buisson A, Giraud S, Lasset C, Bonadona V, Trédan O, Labidi-Galy SI. Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypes. Sci Rep. 2020 Apr 27;10(1):7073.
• Le Page C, Rahimi K, Rodrigues M, Heinzelmann-Schwarz V, Recio N, Tommasi S, Bataillon G, Portelance L, Golmard L, Meunier L, Tonin PN, Gotlieb W, Yasmeen A, Ray-Coquard I, Labidi-Galy SI, Provencher D, Mes-Masson AM. Clinicopathological features of women with epithelial ovarian cancer and double heterozygosity for BRCA1 and BRCA2: A systematic review and case report analysis. Gynecol Oncol. 2020 Feb;156(2):377-386.

2019

• Labidi-Galy SI, de La Motte Rouge T, Derbel O, Wolfer A, Kalbacher E, Olivier T, Combes JD, Heimgartner-Hu K, Tredan O, Guevara H, Heudel PE, Reverdy T, Bazan F, Heinzelmann-Schwarz V, Fehr M, de Castelbajac V, Vaflard P, Crivelli L, Bonadona V, Viassolo V, Buisson A, Golmard L, Rodrigues M, Ray-Coquard I. Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers. Gynecol Oncol. 2019 Nov;155(2):262-269.
• Friedlaender A, Vuilleumier A, Viassolo V, Ayme A, De Talhouet S, Combes JD, Peron J, Bodmer A, Giraud S, Buisson A, Bonadona V, Gauchat-Bouchardy I, Tredan O, Chappuis PO, Labidi-Galy SI. BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients. BreastCancer Res Treat. 2019 Apr;174(3):775-783.

2018

• Elias KM, Tsantoulis P, Tille JC, Vitonis A, Doyle LA, Hornick JL, Kaya G, Barnes L, Cramer DW, Puppa G, Stuckelberger S, Hooda J, Dietrich PY, Goggins M, Kerr CL, Birrer M, Hirsch MS, Drapkin R, Labidi-Galy SI. Primordial germ cells as a potential shared cell of origin for mucinous cystic neoplasms of the pancreas and mucinous ovarian tumors. J Pathol. 2018 Dec;246(4):459-469.
• Labidi-Galy SI, Olivier T, Rodrigues M, Ferraioli D, Derbel O, BodmerA, PetignatP, RakB, ChopinN, Chappuis P, Bonadona V, Ray-Coquard I. Location of mutation in BRCA2 gene and survival in patients with ovarian cancer. Clin Cancer Res 2018 Jan 15;24(2):326-333.

2017

• Labidi-Galy SI, Papp E, Hallberg D, Niknafs N, Adleff V, Noe M, Bhattacharya R, Novak M, Jones S, Phallen J, Hruban CA, Hirsch MS, Lin DI, Schwartz L, Maire CL, Tille JC, Bowden M, Scharpf RB, Kurman R, Wang TL, Shih IM, Karchin R, Drapkin R, Velculescu VE. High grade serous ovarian carcinomas originate in the fallopian tube. Nature Communications 2017 Oct 23;8(1):1093.
• Ballestro A, Bedognetti D, Ferraioli D, Labidi-Galy SI, Leo E, Murai J, Pommier Y, Tsantoulis P, Vellone VG, Zoppoli G. Report on the first SLFN11 monothematic workshop: from function to role as a biomarker in cancer. J Transl Med 2017 Oct 2;15(1):199.
• Vuillemier A, Labidi-Galy SI. Dépistage du cancer de l’ovaire : ce n’est pas pour demain [Screening of ovarian cancer: Not for tomorrow]. Rev Med Suisse. 2017 May 17;13(563):1039-1041.

2016

• De Picciotto N, Cacheux W, Roth A, Chappuis PO, Labidi-Galy SI. Ovarian cancer: status of homologous recombination pathway as a predictor of drug response. Crit Rev Oncol Hematol 2016; 101: 50-9.

2015

• Labidi-Galy SI, Clauss A, Ng V, Duraisamy S, Elias KM, Piao HY, Bilal E, Davidowitz RA, Lu Y, Badalian-Very G, Györffy B, Kang UB, Ficarro S, Ganesan S, Mills GB, Marto JA, Drapkin R. Elafin drives poor outcome in high grade serous ovarian cancers and basal-like breast tumors’. Oncogene 2015; 34(3): 373-83. https://www.ncbi.nlm.nih.gov/pubmed/24469047.

2014

• Williams KA, Labidi-Galy SI, Terry KL, Vitonis AF, Welch WR, Goodman A, Cramer DW. Prognostic significance and predictors of the neutrophil-to-lymphocyte ratio in ovarian cancer. Gynecol Oncol. 2014 Mar; 132(3):542-50. https://www.ncbi.nlm.nih.gov/pubmed/24462730.
• Elias KM, Labidi-Galy SI, Vitonis AF, Hornick JL, Doyle LA, Hirsch MS, Cramer DW, Drapkin R. Prior appendectomy does not protect against subsequent development of malignant or borderline mucinous ovarian neoplasms. Gynecol Oncol. 2014 Feb; 132(2):328-33. https://www.ncbi.nlm.nih.gov/pubmed/24342438.

2013

• Sisirak V, Vey N, Goutagny N, Renaudineau S, Malfroy M, Thys S, Treilleux I, Labidi-Galy SI, Bachelot T, Ménétrier-Caux C, Blay JY, Caux C, and Bendriss-Vermare N. Breast cancer-derived TGF-ß and TNF-α compromise IFN- α production by tumor-associated plasmacytoid dendritic cells. Int J Cancer 2013 133(3):771-8. https://www.ncbi.nlm.nih.gov/pubmed/23389942

2012

• Péron J, Cropet C, Tredan O, Bachelot T, Ray-Coquard I, Clapisson G, Chabaud S, Philip I, Borg C, Cassier P, Labidi Galy I, Sebban C, Perol D, Biron P, Caux C, Menetrier-Caux C, Blay JY. CD4 lymphopenia to identify end-of-life metastatic cancer patients. Eur J Cancer. 2012; 49(5):1080-9. https://www.ncbi.nlm.nih.gov/pubmed/23246297
• Sisirak V, Faget J, Gobert M, Treilleux I, Renaudineau S, Poyet G, Labidi-Galy SI, Goddard-Leon S, Durand I, Goutagny N, Le Mercier I, Bachelot T, Ray-Coquard I, Puisieux A, Ménétrier-Caux C, Blay JY, Caux C, Bendriss-Vermare N. Impaired IFN-α production by plasmacytoid dendritic cells favors regulatory T cells expansion that may contribute to breast cancer progression. Cancer Res. 2012 Oct 15; 72(20):5188-97. https://www.ncbi.nlm.nih.gov/pubmed/22836755
• Manuel M, Tredan O, Bachelot T, Clapisson G, Courtier A, Parmentier G, Rabeony T, Grives A, Perez S, Mouret JF, Perol D, Chabaud S, Ray-Coquard I, Labidi-Galy I, Heudel P, Pierga JY, Caux C, Blay JY, Pasqual N, Ménétrier-Caux C. Lymphopenia combined with low TCR diversity (divpenia) predicts poor overall survival in metastatic breast cancer patients. Oncoimmunology. 2012 Jul 1; 1(4):432-440. https://www.ncbi.nlm.nih.gov/pubmed/22754761
• Labidi-Galy SI, Treilleux I, Goddard-Leon S, Combes JD, Blay JY, Ray-Coquard I, Caux C, and Bendriss-Vermare N. Plasmacytoid dendritic cells infiltrating ovarian cancer are associated with poor prognosis. Oncoimmunology. 2012 3 (1): 1-3. https://www.ncbi.nlm.nih.gov/pubmed/22737622

2011

• Labidi-Galy SI, Sisirak V, Meeus P, Gobert M, Treilleux I, Bajard A, Combes JD, Faget J, Mithieux F, Cassignol A, Tredan O, Durand I, Ménétrier-Caux CCaux C, Blay JY, Ray-Coquard I, Bendriss-Vermare N. Quantitative and functional alterations of plasmacytoid dendritic cell in cancer contribute to immune tolerance. Cancer Res. 2011 Aug 15; 71(16):5423-34. https://www.ncbi.nlm.nih.gov/pubmed/21697280

2003-2010

• Ray-Coquard I, Cropet C, Van Glabbeke M, Sebban C, Le Cesne A, Judson I, Tredan O, Verweij J, Biron P, Labidi I, Guastalla JP, Bachelot T, Perol D, Chabaud S, Hogendoorn PC, Cassier P, Dufresne A, Blay JY; European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res. 2009; 69(13):5383-91. https://www.ncbi.nlm.nih.gov/pubmed/19549917
• Labidi SI, Ménétrier-Caux C, Chabaud S, Chassagne C, Sebban C, Gargi T, Biron P, Blay JY, Ghesquières H. Serum cytokines in follicular lymphoma. Correlation of TGF-beta and VEGF with survival. Ann Hematol. 2010; 89:25-33. https://www.ncbi.nlm.nih.gov/pubmed/19582455
• Bachelot T, Le Rhun E, Labidi-Gally I, Heudel P, Gilabert M, Bonneterre J, Pierga JY, Gonçalves A. Systemic treatment of brain metastases from breast cancer: cytotoxic chemotherapy and targeted therapies. Bull Cancer. 2013 Jan 1;100(1):7-14. https://www.ncbi.nlm.nih.gov/pubmed/23305997
• Peron J, Tredan O, Ray-Coquard I, Bachelot T, Labidi-Galy SI, Favier B, Treilleux I, Guastalla JP. First-line endocrine therapy alone could be a reasonable treatment option for hormone-positive, HER2-positive metastatic breast cancer. Bull Cancer 2012. 2012 Feb 1;99 (2):E18-25. https://www.ncbi.nlm.nih.gov/pubmed/22257781
• Cassier PA, Labidi-Galy SI, Heudel P, Dutour A, Méeus P, Chelghoum M, Alberti L, Ray-Coquard I, Blay JY. Therapeutic pipeline for soft-tissue sarcoma. Expert Opin Pharmacother. 2011 Nov;12(16):2479-91. https://www.ncbi.nlm.nih.gov/pubmed/21913865
• Asmane I, Kurtz JE, Bajard A, Guastalla JP, Meeus P, Tredan O, Labidi-Galy I, Moullet I, Ardisson P, Vincent L, Coeffic D, Dufresne A, Bergerat JP, Ray-Coquard I. Bevacizumab plus microtubule targeting agents in heavily pre-treated ovarian cancer patients: a retrospective study. Bull Cancer. 2011 Oct;98(9):80-9. https://www.ncbi.nlm.nih.gov/pubmed/21926034
• Galy G, Labidi-Galy SI, Perol D, Bachelot T, Ray-Coquard I, Tredan O, Blay JY, Latour JF,JP Guastalla, B Favier. Metastatic breast cancer treated by chemotherapy: Comparison of clinical practice and costs of drugs in two cohorts of patients: 1994-1998 and 2003-2006. Breast Cancer Res Treat. 2011 Jul; 128(1):187-95. https://www.ncbi.nlm.nih.gov/pubmed/21184270
• Carrabin N, Mithieux F, Meeus P, Trédan O, Guastalla JP, Bachelot T, Labidi-Galy SI, Treilleux I^, Rivoire M, Ray-CoquardI. Hyperthermic intraperitoneal chemotherapy (HIPEC) using oxaliplatin for stage IIIC ovarian cancer without adjuvant chemotherapy. Bull Cancer. 2010 Apr; 97(4):E23-32. https://www.ncbi.nlm.nih.gov/pubmed/20202920
• Galy G, Labidi SI, Tissier F, Combes JD, Auger A, Favier B, Latour JF. Aprepitant for the prevention of cisplatine induced nausea and vomiting: an observational study. Bull Cancer. 2009; 96(2):141-5. https://www.ncbi.nlm.nih.gov/pubmed/19258220
• Labidi SI, Bachelot T, Ray-Coquard I, Mosbah K, Treilleux I, Fayette J, Favier B, Galy G, Blay JY, Guastalla JP. Bevacizumab and paclitaxel for breast cancer patients with central nervous system metastases: a case series. Clin Breast Cancer. 2009; 9(2):118-21. https://www.ncbi.nlm.nih.gov/pubmed/19433393
• Cassier PA, Dufresne A, Arifi S, El Sayadi H, Labidi I, Ray-Coquard I, Tabone S, Méeus P, Ranchère D, Sunyach MP, Decouvelaere AV, Alberti L, Blay JY. Imatinib mesilate for the treatment of gastrointestinal stromal tumour. Expert Opin Pharmacother. 2008; 9(7):1211-22. https://www.ncbi.nlm.nih.gov/pubmed/18422477
• Labidi SI, Sebban C, Ghesquieres H, Virelizier Nicolas E, Pierre Biron. Hepatic veno-occlusive disease after tandem autologous stem cell transplantation conditionned by melphalan. Int J Hematol. 2008; 88(3):291-3. https://www.ncbi.nlm.nih.gov/pubmed/18696182
• Labidi SI, M’rad K, Mezlini A, Ouarda MA, Combes JD, Ben Abdallah M, Ben Romdhane K, Viens P, Ben Ayed F. Tunisian inflammatory breast cancer in the era of multimodality therapy. Ann Oncol. 2008; 19(3):473-80. https://www.ncbi.nlm.nih.gov/pubmed/18006895
• Ben Hamida A, Intidhar Labidi S, M’rad K, Charafe-Jauffret E, Ben Arab S, Esterni B, Xerri L, Viens P, Bertucci F, Birnbaum D, Jacquemier J. P-cadherin expression characterizes inflammatory breast cancer. BMC cancer. 2008; 8:28. https://www.ncbi.nlm.nih.gov/pubmed/18230143
• Labidi SI, Gravis G, Tarpin C, Brun V, Viens P. Medullary thyroid cancer treated by capecitabine. Anticancer Drugs. 2007; 18(7): 831-4. https://www.ncbi.nlm.nih.gov/pubmed/17581307
• Intidhar Labidi S, Chaabouni AM, Kraiem T, Attia N, Gritli S, El May A, Ben Slimane F. Thyroid carcinoma and Hashimoto thyroiditis. Ann Otolaryngol Chir Cervicofac. 2006; 123(4):175-8. https://www.ncbi.nlm.nih.gov/pubmed/17088704
• Charaffe-Jaufret E, M’rad K, Intidhar Labidi S, Ben Hamida A, Ben Romdhane K, Ben Abdallah M, Ginestier C, Esterni B, Birnbaum D, Ben Ayed F, Xerri L, Viens P, Mezlini A, Jacquemier J. Inflammatory breast cancers in Tunisia and France show similar immunophenotypes. Breast. 2007; 16: 352-8. https://www.ncbi.nlm.nih.gov/pubmed/17360185
• Chaabouni AM, Intidhar Labidi S, Kraiem T, Gammoudi A, Ladgham A, Ben Slimane F. Papillary-follicular carcinoma arising in a lingual thyroid. Ann Otolaryngol Chir Cervicofac. 2006; 123(4):199-202. https://www.ncbi.nlm.nih.gov/pubmed/17088708